INVO Bioscience, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by INVO Bioscience, Inc. (trading symbol: INVO) on January 6, 2022, covering the event date of December 31, 2021. The company is incorporated in Nevada and its principal executive offices are located in Sarasota, Florida.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or margin data. The only specific financial figures disclosed relate to a capital transaction:
- Transaction Value: $1,999,740.29 aggregate purchase price.
- Shares Sold: 600,703 shares of common stock.
- Price Per Share: $3.329.
Information regarding debt levels, liquidity ratios, and operating cash flow is not present in this document.
Material Changes
The primary material change reported is the execution of a Second Amendment to a Stock Purchase Agreement with Paradigm Opportunities Fund, LP. This amendment extended the closing date for the sale of 600,703 shares from December 31, 2021, to January 31, 2022. The original agreement was dated October 1, 2021, and had previously been amended once to extend the closing to December 31, 2021.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or specific risk factors beyond the standard legal disclaimer that the summary of the Second Amendment is qualified by reference to the full text of the agreement filed as Exhibit 10.1. No unusual items or contingencies were disclosed in the text provided.
Key Facts for Investor Verification
- Verify the final closing status of the $1,999,740.29 stock sale with Paradigm Opportunities Fund, LP, as the deadline was extended to January 31, 2022.
- Review the full text of the Second Amendment (Exhibit 10.1) for any additional covenants or conditions not summarized in the 8-K.
- Confirm the impact of this equity issuance on total share count and potential dilution, as the filing does not provide post-transaction capitalization tables.